BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eso Y, Shimizu T, Takeda H, Takai A, Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol 2020;55:15-26. [PMID: 31494725 DOI: 10.1007/s00535-019-01620-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 18.3] [Reference Citation Analysis]
Number Citing Articles
1 Taherian M, Wang H, Wang H. Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers. Cells 2022;11:3068. [DOI: 10.3390/cells11193068] [Reference Citation Analysis]
2 Ren P, Zhang Y. Focus on pattern recognition receptors to identify prognosis and immune microenvironment in colon cancer. Front Oncol 2022;12:1010023. [DOI: 10.3389/fonc.2022.1010023] [Reference Citation Analysis]
3 Wei S, Gu X, Zhang W. Development and validation of a novel fibroblast scoring model for lung adenocarcinoma. Front Oncol 2022;12:905212. [DOI: 10.3389/fonc.2022.905212] [Reference Citation Analysis]
4 Gu X, Zheng S, Zhang H, Sun X, Zhou Q. The cross-talk of cancer-associated fibroblasts assist in prognosis and immunotherapy in patients with breast carcinoma. Cancer Gene Ther 2022. [PMID: 35948763 DOI: 10.1038/s41417-022-00514-w] [Reference Citation Analysis]
5 Yang J, Chen H, Wang Y, Chen J. Development and validation of a robust necroptosis related classifier for colon adenocarcinoma. Front Genet 2022;13:965799. [DOI: 10.3389/fgene.2022.965799] [Reference Citation Analysis]
6 Amato M, Franco R, Facchini G, Addeo R, Ciardiello F, Berretta M, Vita G, Sgambato A, Pignata S, Caraglia M, Accardo M, Zito Marino F. Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers. Int J Mol Sci 2022;23:8726. [PMID: 35955855 DOI: 10.3390/ijms23158726] [Reference Citation Analysis]
7 Tsumura T, Doi K, Marusawa H. Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. Cancers 2022;14:3674. [DOI: 10.3390/cancers14153674] [Reference Citation Analysis]
8 Wu D, Chen Q, Chen J. Case Report: Malignant Brain Tumors in Siblings With MSH6 Mutations. Front Oncol 2022;12:920305. [DOI: 10.3389/fonc.2022.920305] [Reference Citation Analysis]
9 Qiu W, Yang J, Wang B, Yang M, Tian G, Wang P, Yang J. Evaluating the Microsatellite Instability of Colorectal Cancer Based on Multimodal Deep Learning Integrating Histopathological and Molecular Data. Front Oncol 2022;12:925079. [DOI: 10.3389/fonc.2022.925079] [Reference Citation Analysis]
10 Brown ZJ, Gregory S, Hewitt DB, Iacono S, Choe J, Labiner HE, Pawlik TM. Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surgical Oncology 2022;42:101748. [DOI: 10.1016/j.suronc.2022.101748] [Reference Citation Analysis]
11 Chu XD, Lin ZB, Huang T, Ding H, Zhang YR, Zhao Z, Huangfu SC, Qiu SH, Guo YG, Chu XL, Pan JH, Pan YL. Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer. BMC Cancer 2022;22:250. [PMID: 35255858 DOI: 10.1186/s12885-022-09201-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Muhammed A, D'Alessio A, Enica A, Talbot T, Fulgenzi CAM, Nteliopoulos G, Goldin RD, Cortellini A, Pinato DJ. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35236211 DOI: 10.1080/14737159.2022.2049244] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
13 Tong H, Wei H, Smith AO, Huang J. The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. Front Immunol 2021;12:802049. [PMID: 35069586 DOI: 10.3389/fimmu.2021.802049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Do MD, Nguyen TH, Le KT, Le LHG, Nguyen BH, Le KT, Doan TPT, Ho CQ, Nguyen HN, Tran TD, Vu HA. Molecular characteristics of young-onset colorectal cancer in Vietnamese patients. Asia Pac J Clin Oncol 2022. [PMID: 35098669 DOI: 10.1111/ajco.13749] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Crit Rev Oncol Hematol 2022;:103597. [PMID: 35033663 DOI: 10.1016/j.critrevonc.2022.103597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 Lin B, Wang Y, Zhao K, Lü WD, Hui X, Ma Y, Lv R. Exosome-based rare earth nanoparticles for targeted in situ and metastatic tumor imaging with chemo-assisted immunotherapy. Biomater Sci 2021. [PMID: 34940770 DOI: 10.1039/d1bm01809d] [Reference Citation Analysis]
17 Goggi JL, Ramasamy B, Tan YX, Hartimath SV, Tang JR, Cheng P, Msallam R, Chacko A, Hwang YY, Robins EG, Bogdanov A. Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma. Molecular Imaging 2021;2021:1-8. [DOI: 10.1155/2021/9305277] [Reference Citation Analysis]
18 Sankarasubramanian S, Pfohl U, Regenbrecht CRA, Reinhard C, Wedeken L. Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Front Cell Dev Biol 2021;9:760705. [PMID: 34805167 DOI: 10.3389/fcell.2021.760705] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Eso Y, Seno H. Optimization of immunotherapy for patients with hepatobiliary cancer. Hepatobiliary Surg Nutr 2021;10:717-9. [PMID: 34760984 DOI: 10.21037/hbsn-21-207] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Lu Z, Chen H, Jiao X, Wang Y, Wu L, Sun H, Li S, Gong J, Li J, Zou J, Yang K, Hu Y, Mao B, Zhang L, Zhang X, Peng Z, Lu M, Wang Z, Zhang H, Shen L. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. Genome Med 2021;13:175. [PMID: 34732240 DOI: 10.1186/s13073-021-00997-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Prete MG, Cammarota A, D'alessio A, Zanuso V, Rimassa L. Current options and future directions of systemic therapy for advanced biliary tract cancer. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00054] [Reference Citation Analysis]
22 Kim BH, Park J. Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment. J Liver Cancer 2021;21:124-38. [DOI: 10.17998/jlc.2021.09.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Weis LN, Tolaney SM, Barrios CH, Barroso-Sousa R. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? NPJ Breast Cancer 2021;7:120. [PMID: 34518552 DOI: 10.1038/s41523-021-00328-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J Hepatocell Carcinoma 2021;8:887-97. [PMID: 34386437 DOI: 10.2147/JHC.S284440] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
25 Freed-Pastor WA, Lambert LJ, Ely ZA, Pattada NB, Bhutkar A, Eng G, Mercer KL, Garcia AP, Lin L, Rideout WM 3rd, Hwang WL, Schenkel JM, Jaeger AM, Bronson RT, Westcott PMK, Hether TD, Divakar P, Reeves JW, Deshpande V, Delorey T, Phillips D, Yilmaz OH, Regev A, Jacks T. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell 2021:S1535-6108(21)00384-6. [PMID: 34358448 DOI: 10.1016/j.ccell.2021.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
26 Shi R, Li Y, Ran L, Dong Y, Zhou X, Tang J, Han L, Wang M, Pang L, Qi Y, Wu Y, Gao Y. Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy of non-microsatellite instability-high colorectal cancer. Sci China Life Sci 2021. [PMID: 34236583 DOI: 10.1007/s11427-021-1944-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Yoon SJ, Lee CB, Chae SU, Jo SJ, Bae SK. The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy. Int J Mol Sci 2021;22:6932. [PMID: 34203237 DOI: 10.3390/ijms22136932] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Wang H, Liu B, Wei J. Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy. Cancer Lett 2021;517:96-104. [PMID: 34129878 DOI: 10.1016/j.canlet.2021.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kai Y, Ikezawa K, Takada R, Daiku K, Maeda S, Abe Y, Yamai T, Fukutake N, Nakabori T, Uehara H, Nagata S, Wada H, Ohkawa K. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer. JGH Open 2021;5:712-6. [PMID: 34124390 DOI: 10.1002/jgh3.12576] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
30 Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Guerini-Rocco E, Haricharan S, Fusco N. Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. Cancer Cell Int 2021;21:266. [PMID: 34001143 DOI: 10.1186/s12935-021-01976-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ma W, Pham B, Li T. Cancer neoantigens as potential targets for immunotherapy. Clin Exp Metastasis 2021. [PMID: 33950415 DOI: 10.1007/s10585-021-10091-1] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
32 Kiaie SH, Sanaei MJ, Heshmati M, Asadzadeh Z, Azimi I, Hadidi S, Jafari R, Baradaran B. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharm Sin B 2021;11:1083-97. [PMID: 34094821 DOI: 10.1016/j.apsb.2020.12.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
33 Eso Y, Seno H. Synergistic effects of anti-angiogenesis and immune checkpoint blockade - a new era of systemic chemotherapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:493-5. [PMID: 33906802 DOI: 10.1016/j.hbpd.2021.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zhang Y, Wang F, Sun HR, Huang YK, Gao JP, Huang H. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer. J Cancer Res Clin Oncol 2021;147:2209-22. [PMID: 33891173 DOI: 10.1007/s00432-021-03633-3] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
35 Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
36 Fathi M, Pustokhina I, Kuznetsov SV, Khayrullin M, Hojjat-Farsangi M, Karpisheh V, Jalili A, Jadidi-Niaragh F. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. IUBMB Life 2021;73:726-38. [PMID: 33686787 DOI: 10.1002/iub.2461] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
37 Thakur N, Paik KY, Hwang G, Chong Y. High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition. Diagnostics (Basel) 2021;11:597. [PMID: 33810560 DOI: 10.3390/diagnostics11040597] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, Gueorguieva I, Man M, Gandhi L, Estrem ST, Benhadji KA, Lanasa MC, Avsar E, Guba SC, Garcia-Carbonero R. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J Immunother Cancer 2021;9:e002068. [PMID: 33688022 DOI: 10.1136/jitc-2020-002068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
39 Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I. Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol 2020;4:PO. [PMID: 33542969 DOI: 10.1200/PO.20.00052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Mei Y, Bi WL, Agolia J, Hu C, Giantini Larsen AM, Meredith DM, Al Abdulmohsen S, Bale T, Dunn GP, Abedalthagafi M, Dunn IF. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary 2021;24:359-73. [PMID: 33492612 DOI: 10.1007/s11102-020-01114-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
41 Zeng Z, Yang B, Liao Z. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. Future Oncol 2021;17:1553-69. [PMID: 33397136 DOI: 10.2217/fon-2020-0829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Valieris R, Amaro L, Osório CABT, Bueno AP, Rosales Mitrowsky RA, Carraro DM, Nunes DN, Dias-Neto E, Silva ITD. Deep Learning Predicts Underlying Features on Pathology Images with Therapeutic Relevance for Breast and Gastric Cancer. Cancers (Basel) 2020;12:E3687. [PMID: 33316873 DOI: 10.3390/cancers12123687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
43 Ciernikova S, Novisedlakova M, Cholujova D, Stevurkova V, Mego M. The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma.Biomedicines. 2020;8. [PMID: 33287196 DOI: 10.3390/biomedicines8120565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
44 Bazzichetto C, Luchini C, Conciatori F, Vaccaro V, Di Cello I, Mattiolo P, Falcone I, Ferretti G, Scarpa A, Cognetti F, Milella M. Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. Int J Mol Sci 2020;21:E8841. [PMID: 33266496 DOI: 10.3390/ijms21228841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
45 Karamitopoulou E. The Tumor Microenvironment of Pancreatic Cancer. Cancers (Basel) 2020;12:E3076. [PMID: 33096881 DOI: 10.3390/cancers12103076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
46 Lopez G, Venetis K, Sajjadi E, Fusco N. Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing. GastrointestDisord 2020;2:341-52. [DOI: 10.3390/gidisord2040031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Xue Y, Balci S, Aydin Mericoz C, Taskin OC, Jiang H, Pehlivanoglu B, Muraki T, Memis B, Saka B, Kim GE, Bandopadhyay S, Knight J, El-Rayes BF, Sarmiento J, Reid MD, Erkan M, Basturk O, Adsay V. Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. Cancer 2020;126:4788-99. [PMID: 32857459 DOI: 10.1002/cncr.33135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
48 Eso Y, Seno H. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Therap Adv Gastroenterol. 2020;13:1756284820948773. [PMID: 32913444 DOI: 10.1177/1756284820948773] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
49 Sodergren MH, Mangal N, Wasan H, Sadanandam A, Balachandran VP, Jiao LR, Habib N. Immunological combination treatment holds the key to improving survival in pancreatic cancer. J Cancer Res Clin Oncol 2020;146:2897-911. [PMID: 32748119 DOI: 10.1007/s00432-020-03332-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
50 Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
51 Yamamoto H, Watanabe Y, Maehata T, Imai K, Itoh F. Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach. Arch Toxicol 2020;94:3349-57. [DOI: 10.1007/s00204-020-02833-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
52 Eso Y. Microsatellite instability analysis using multiplex polymerase chain reaction with fluorescently labeled primers for amplification of five mononucleotide repeat markers. Hepatol Res 2020;50:1391-2. [PMID: 32618030 DOI: 10.1111/hepr.13542] [Reference Citation Analysis]
53 Chen J, Quan M, Chen Z, Zeng T, Li Y, Zhou Y, Hai Y, Gao Y. Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial. J Cancer Res Clin Oncol 2020;146:2651-7. [PMID: 32623573 DOI: 10.1007/s00432-020-03251-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
54 Saleh R, Toor SM, Al-Ali D, Sasidharan Nair V, Elkord E. Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. Genes (Basel) 2020;11:E703. [PMID: 32616706 DOI: 10.3390/genes11060703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
55 Haen SP, Löffler MW, Rammensee HG, Brossart P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol 2020;17:595-610. [PMID: 32572208 DOI: 10.1038/s41571-020-0387-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 55] [Article Influence: 14.0] [Reference Citation Analysis]
56 Abdul-Latif M, Townsend K, Dearman C, Shiu KK, Khan K. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treat Rev 2020;88:102030. [PMID: 32505807 DOI: 10.1016/j.ctrv.2020.102030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
57 Nelson SR, Walsh N. Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. Cancers (Basel) 2020;12:E1233. [PMID: 32423157 DOI: 10.3390/cancers12051233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
58 Thanh Huong P, Gurshaney S, Thanh Binh N, Gia Pham A, Hoang Nguyen H, Thanh Nguyen X, Pham-The H, Tran PT, Truong Vu K, Xuan Duong N, Pelucchi C, La Vecchia C, Boffetta P, Nguyen HD, Luu HN. Emerging Role of Circulating Tumor Cells in Gastric Cancer. Cancers (Basel) 2020;12:E695. [PMID: 32183503 DOI: 10.3390/cancers12030695] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]